Cagrilintide Research for Type 2 Diabetes
An evidence-based overview of research examining Cagrilintide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
CagriSema demonstrated superior glycemic control vs semaglutide alone in Phase 2 trial of T2D patients. HbA1c reduction of -2.2% with CagriSema vs -1.8% with semaglutide. Amylin analogs suppress postprandial glucagon and slow gastric emptying, contributing to glucose control.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Type 2 Diabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Cagrilintide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.